Skip to main content
. 2021 Nov 4;9(11):e002837. doi: 10.1136/jitc-2021-002837

Figure 6.

Figure 6

BXCL701 +anti-PD1 combination treatment is dependent on both CD8+ T cells and NK cells. (A) Schematic representation of in vivo experiment design testing effect of CD8+ T cell and NK cell depletion on combination treatment (BXCL701 +anti-PD1) efficacy in mT3-2D tumors. (B) Average mT3-2D tumor growth curves in C57BL/6 mice treated with PBS (n=10), BXCL701 +anti-PD1 combination (n=10), combination with NK1.1+ NK cell depletion (n=5), combination with CD8+ T cell depletion (n=5), or combination with NK1.1+ NK cell depletion and CD8+ T cell depletion (n=5). Tumor growth was monitored weekly. (C) Tumor volumes after 4 weeks of treatment (day 32) for mT3-2D tumors treated with PBS, BXCL701+anti-PD1 combination (‘Combo’), combo with NK1.1+cell depletion, combo with CD8 + T cell depletion or combo with both NK1.1+ and CD8+ T cell depletion. (ns=non-significant, **p<0.01,***p<0.001, ****p<0.0001 as determined by analysis of variance followed by Tukey’s multiple comparison’s test). (D) Individual tumor growth curves for treatment-naive C57BL/6 mice (n=5) and previously ‘cured’ C57BL/6 mice (n=13) injected with 5×105 mT3-2D cells. Tumor growth was monitored three times a week. (E) mT3-2D tumor volumes in treatment-naive C57BL/6 mice and previously ‘cured’ C57BL/6 mice 40 days after injection of 5×105 mT3-2D cells. (****p<0.0001 by unpaired two-tailed t-test). PBS, phosphate-buffered saline.